16 31

Cited 3 times in

Molecular Testing of Lung Cancers

Authors
 Hyo Sup Shim  ;  Yoon-La Choi  ;  Lucia Kim  ;  Sunhee Chang  ;  Wan-Seop Kim  ;  Mee Sook Roh  ;  Tae-Jung Kim  ;  Seung Yeon Ha  ;  Jin-Haeng Chung  ;  Se Jin Jang  ;  Geon Kook Lee  ;  The Korean Cardiopulmonary Pathology Study Group  ;  and The Korean Molecular Pathology Study Group 
Citation
 Journal of Pathology and Translational Medicine, Vol.51(3) : 242-254, 2017 
Journal Title
 Journal of Pathology and Translational Medicine 
ISSN
 2383-7837 
Issue Date
2017
Keywords
Guideline ; Lung neopla는 ; Molecular testing ; Precision medicine
Abstract
Targeted therapies guided by molecular diagnostics have become a standard treatment of lung cancer. Epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements are currently used as the best predictive biomarkers for EGFR tyrosine kinase inhibitors and ALK inhibitors, respectively. Besides EGFR and ALK, the list of druggable genetic alterations has been growing, including ROS1 rearrangements, RET rearrangements, and MET alterations. In this situation, pathologists should carefully manage clinical samples for molecular testing and should do their best to quickly and accurately identify patients who will benefit from precision therapeutics. Here, we grouped molecular biomarkers of lung cancers into three categories-mutations, gene rearrangements, and amplifications-and propose expanded guidelines on molecular testing of lung cancers.
Files in This Item:
T201702711.pdf Download
DOI
10.4132/jptm.2017.04.10
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
Yonsei Authors
심효섭(Shim, Hyo Sup) ORCID logo https://orcid.org/0000-0002-5718-3624
Export
RIS (EndNote)
XLS (Excel)
XML
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/160591
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse